Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0000582

Prednisolone 21-acetate

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

21-acétate de 1,4-pregnadiène-11β,17α,21-triol-3,20-dione, 21-acétate de 11β,17α,21-trihydroxy-1,4-pregnadiène-3,20-dione

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C23H30O6
Numéro CAS:
52-21-1
Poids moléculaire :
402.48
Numéro Beilstein :
3111798
Numéro MDL:
MFCD00037710
Code UNSPSC :
41116107
ID de substance PubChem :
329831032
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

prednisolone

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)COC(C)=O

InChI

1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-18,20,26,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1

Clé InChI

LRJOMUJRLNCICJ-JZYPGELDSA-N

Informations sur le gène

human ... NR3C1(2908)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Prednisolone acetate for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

PHR1043

Prednisolone, Pharmaceutical Secondary Standard; Certified Reference Material

P2700000

Prednisolone, European Pharmacopoeia (EP) Reference Standard

P2800000

Prednisolone 21-acetate, European Pharmacopoeia (EP) Reference Standard

P2810000

Prednisolone sodium phosphate, European Pharmacopoeia (EP) Reference Standard

Y0001355

Prednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001359

Prednisolone for peak identification, European Pharmacopoeia (EP) Reference Standard

P2805000

Prednisolone pivalate, European Pharmacopoeia (EP) Reference Standard

1557000

Prednisolone sodium phosphate, United States Pharmacopeia (USP) Reference Standard

1555005

Prednisolone, United States Pharmacopeia (USP) Reference Standard

1556008

Prednisolone 21-acetate, United States Pharmacopeia (USP) Reference Standard

1556507

Prednisolone hemisuccinate, United States Pharmacopeia (USP) Reference Standard

1558003

Prednisolone tebutate, United States Pharmacopeia (USP) Reference Standard

BP464

Prednisolone, British Pharmacopoeia (BP) Assay Standard

BP292

Prednisolone sodium phosphate, British Pharmacopoeia (BP) Assay Standard

PHR1630

Prednisolone 21-acetate, Pharmaceutical Secondary Standard; Certified Reference Material

BP1140

Prednisolone 21-acetate, British Pharmacopoeia (BP) Reference Standard

PHR2556

Prednisolone Impurity H, Pharmaceutical Secondary Standard; Certified Reference Material, certified reference material, pharmaceutical secondary standard

PHR2557

Prednisolone Impurity I, certified reference material, pharmaceutical secondary standard

PHR2328

Prednisolone Impurity G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2816

Prednisolone Sodium Phosphate, certified reference material, pharmaceutical secondary standard

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H360FD

Classification des risques

Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Salima I Hassanaly et al.
American journal of ophthalmology, 158(2), 270-276 (2014-05-23)
To describe outcomes after Boston Type 1 Keratoprosthesis (KPro) surgery in aniridic eyes. Retrospective, interventional case series. University-based tertiary care institution. Twenty-six aniridic eyes of 19 patients who underwent KPro implantation by a single experienced surgeon (M.H.-D.) between October 27
Marcus Ang et al.
American journal of ophthalmology, 157(6), 1163-1169 (2014-03-04)
To compare 3-year endothelial cell loss and graft survival following Descemet stripping automated endothelial keratoplasty (DSAEK) using the EndoGlide (AngioTech, Reading, Pennsylvania, USA/Network Medical Products, North Yorkshire, UK) donor insertion device compared to donor insertion using the Sheets glide technique.
Wool Suh et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 29(7), 646-651 (2013-04-30)
To evaluate the effect of bevacizumab in trabeculectomies with 5-fluorouracil (5-FU). Thirty-six patients with uncontrolled glaucoma were included. Twelve patients underwent trabeculectomies with intracameral and subconjunctival injections of bevacizumab (1.25 mg/0.05 mL) and subconjunctival injections of 5-FU (5.0 mg/0.5 mL). The control group underwent
Rohit Shetty et al.
American journal of ophthalmology, 159(3), 419-425 (2014-12-03)
To evaluate the effect of keratoconus cone location on the change in refractive outcomes, corneal aberrations, and biomechanics after combined topography-guided photorefractive keratectomy (PRK) and collagen cross-linking (CXL). Prospective, comparative case series. Topography-guided PRK was performed followed by accelerated CXL
Rohit Shetty et al.
Indian journal of ophthalmology, 62(9), 923-926 (2014-11-06)
To study the safety and efficacy of sutureless femtosecond anterior lamellar keratoplasty (FALK) in patients with corneal stromal opacities. Eleven eyes of 11 consecutive patients with corneal stromal opacities involving < 250 μ due to various pathologies were included in
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique